RIBOMIC Inc.

4591

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-13FY2027 Q1

Revenue

4,000,000JPY

YoY -

Operating Income

-2.7100M JPY

YoY -14.2%

Net Income

-11.9100M JPY

YoY -19.9%

EPS

-4.9JPY

YoY +4.5%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

80百万円

-3.9億円

-8.5億円

-13.2億円

-17.9億円

Rev: 80百万円Op: -17.5億円NI: -16.8億円

Rev: 65百万円Op: -17.9億円NI: -16.5億円

Rev: -Op: -11.2億円NI: -10.2億円

Rev: 2百万円Op: -10.5億円NI: -10.2億円

Rev: 3百万円Op: -12.1億円NI: -11.5億円

2022/FY2023/FY2024/FY2025/FY2026/FY

Full-Year Progress

FY2027 Q1

Net Income-

Revenue Progress4M

Revenue Forecast17M

Net Income Progress-

Net Income Forecast-

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan